Clinicopathologic and prognostic significance of LGR5, a cancer stem cell marker in patients with colorectal cancer.

IF 2.7 Q3 ONCOLOGY Colorectal Cancer Pub Date : 2019-11-12 DOI:10.2217/crc-2019-0009

Chukwuemeka Ihemelandu, Aisha Naeem, Erika Parasido, Deborah Berry, Krysta Chaldekas, Brent T Harris, Olga Rodriguez, Christopher Albanese

{"title":"Clinicopathologic and prognostic significance of LGR5, a cancer stem cell marker in patients with colorectal cancer.","authors":"Chukwuemeka Ihemelandu, Aisha Naeem, Erika Parasido, Deborah Berry, Krysta Chaldekas, Brent T Harris, Olga Rodriguez, Christopher Albanese","doi":"10.2217/crc-2019-0009","DOIUrl":null,"url":null,"abstract":"Aim: To analyze the clinicopathologic and prognostic significance of Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), a cancer stem cell marker expression in a cohort of colorectal cancer patients (CRC).Patients & methods: A total of 76 formalin-fixed paraffin-embedded tissue blocks of primary or metastatic tumors from 49 CRC patients were collected for duration 2009-2015. LGR5 expression was assessed through immunohistochemical staining of a tissue microarray.Results: LGR5 was significantly over expressed in CRC tissue samples and found to be a statistically significant independent prognostic marker for an improved overall survival.Conclusion: LGR5 expression was higher in colorectal cancer than in normal tissue. LGR5 was an independent prognostic marker for better clinical outcomes and might be used as a potential therapeutic target in CRCs.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"8 4","pages":"CRC11"},"PeriodicalIF":2.7000,"publicationDate":"2019-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/crc-2019-0009","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colorectal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/crc-2019-0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 8

Abstract

Aim: To analyze the clinicopathologic and prognostic significance of Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), a cancer stem cell marker expression in a cohort of colorectal cancer patients (CRC).

Patients & methods: A total of 76 formalin-fixed paraffin-embedded tissue blocks of primary or metastatic tumors from 49 CRC patients were collected for duration 2009-2015. LGR5 expression was assessed through immunohistochemical staining of a tissue microarray.

Results: LGR5 was significantly over expressed in CRC tissue samples and found to be a statistically significant independent prognostic marker for an improved overall survival.

Conclusion: LGR5 expression was higher in colorectal cancer than in normal tissue. LGR5 was an independent prognostic marker for better clinical outcomes and might be used as a potential therapeutic target in CRCs.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

结直肠癌患者肿瘤干细胞标志物LGR5的临床病理及预后意义

目的:分析富亮氨酸重复-含g蛋白偶联受体5 (Leucine-rich repeat-containing G-protein-coupled receptor 5, LGR5)这一肿瘤干细胞标志物在结直肠癌患者(CRC)队列中的表达及其临床病理和预后意义。患者与方法:2009-2015年共收集49例结直肠癌患者原发或转移性肿瘤的76个福尔马林固定石蜡包埋组织块。通过组织芯片的免疫组织化学染色评估LGR5的表达。结果:LGR5在结直肠癌组织样本中显著过表达，是提高总生存率的一个具有统计学意义的独立预后指标。结论:LGR5在结直肠癌组织中的表达高于正常组织。LGR5是一个独立的预后指标，具有较好的临床结果，可能作为治疗crc的潜在靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Colorectal Cancer ONCOLOGY-

自引率

0.00%

发文量

期刊介绍： Colorectal cancer is a major cause of morbidity and mortality, particularly in the developed world. Risk factors for colorectal cancer are on the rise in many countries; populations are aging, and obesity and diabetes are increasing. National screening programs are helping to detect cancer while it is still curable; however, colorectal cancer remains the third leading cause of cancer deaths in the USA and options are still limited for those with more advanced disease. Consequently, colorectal cancer is a major research priority for government, pharmaceutical companies and non-profit organizations. Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. Colorectal Cancer presents reviews, analysis and commentary. on all aspects of colorectal cancer.